Trial Profile
An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Familial Mediterranean fever
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Jul 2018 Results (n=9) published in the Clinical Transplantation.
- 19 Nov 2014 New trial record